|
Delayed
Bombay S.E.
10:57:02 23/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 1,950.00 INR | -2.12% |
|
+0.01% | +36.93% |
| 08-14 | Ipca Laboratories Limited, Q1 2027 Earnings Call, Aug 14, 2026 | |
| 08-13 | Ipca Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
Sales 2026 by Business Segment
Sales 2026 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceuticals | 58.3B | 62.48B | 77.06B | 89.41B | 96.47B | |||||
Total Assets | 76.39B | 86.26B | 111B | 118B | 124B | |||||
Interest Expense | -72.4M | -451M | -1.37B | -843M | -757M | |||||
Income Tax Expense | 2.25B | 2.53B | 3.13B | 3.44B | 3.81B | |||||
CAPEX | -4.79B | -4.94B | -4.11B | -7.76B | -6.56B | |||||
EBT | 11.36B | 7.45B | 8.43B | 11.31B | 15.73B | |||||
D&A | 2.26B | 2.54B | 3.49B | 3.91B | 4.1B | |||||
Net Income | 8.84B | 4.71B | 5.47B | 7.38B | 11.41B |
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
India | 30.11B | 32.65B | 36.14B | 40.42B | 43.87B | |||||
Total Assets | 31.82B | 34.37B | 55.62B | 54.92B | 59.93B | |||||
Outside India (Excluding United Kingdom) | - | - | - | - | 31.2B | |||||
USA | - | - | - | - | 21.4B | |||||
| - | - | - | - | 43.87B | ||||||
United Kingdom | - | - | - | - | - | |||||
outside India | 28.19B | 29.79B | 40.91B | 48.98B | - | |||||
| - | - | - | - | 31.2B | ||||||
| - | - | - | - | 21.4B |
Select your edition
All financial news and data tailored to specific country editions
